Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

MIRMยทNASDAQ

$91.83

-0.016%
HealthcareBiotechnology

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

At a Glance

Live Snapshot
Market Cap$4.61B
EPS-0.4700
P/E Ratio-195.39
Earnings Date07/30/2026

No Dividend Yield Data

MIRM has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MIRM has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MIRM has not reported any net dividends paid values in the available annual periods.

Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. Dividend History

MIRM ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MIRM Dividend Payment History

MIRM ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
mirm

Mirum Pharmaceuticals, Inc. Payout Ratio Analysis

MIRM ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-23.36M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Excellent FCF coverage. Dividend is well-supported by actual cash generation with ample room for increases and business reinvestment.

Sustainability
Fair

Dividend sustainability questionable. Monitor closely for signs of stress. Consider whether yield justifies the risk.